sar425899
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02411825)
Timeline
Indications
Mechanism of action
- Glucagon receptorAGONIST
GCGR agonist
dual glucagon-like peptide-1/glucagon receptor agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545269 ↗
Also known as
- sar425899
- sar425899
- sar-425899
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03437720 | Phase 2 | May 23, 2019 | Sanofi |
| NCT03376802 | Phase 1 | May 1, 2018 | Sanofi |
| NCT03414736 | Phase 1 | Jan 19, 2018 | Sanofi |
| NCT03350191 | Phase 1 | Dec 20, 2017 | Antaros Medical AB, Sanofi |
| NCT02973321 | Phase 2 | Dec 1, 2016 | Sanofi |
| NCT02411825 | Phase 1 | Mar 1, 2015 | Sanofi |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 6 | 6 | 2 | 2015 |
| Antaros Medical AB | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1